Redcare appointed a new CEO. Redcare Pharmacy stock gains 2.21 percent.
Published on 10/21/2026 at 11:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership and guidance in view
- Peter Schmid von Linstow became Redcare Pharmacy CEO on October 14, 2026.
- Full-year 2026 revenue growth guidance rose to 16% to 18%, while the adjusted EBITDA margin remains 2.5% to 3.0%.
- Redcare Pharmacy stock trades at EUR 77.63 at 11:15 a.m. CEST at Lang & Schwarz on October 21, 2026, 2.21 percent above the Xetra close of October 20, 2026.
Redcare Pharmacy (ISIN NL0012044747) was trading at EUR 77.63 at Lang & Schwarz on October 21, 2026, at 11:15 a.m. CEST, up 2.21 percent versus the Xetra close of October 20, 2026, at EUR 75.95. EQS News reported on October 14, 2026, that Peter Schmid von Linstow had been appointed to the Managing Board and as chief executive officer. The leadership change arrives while the company is preparing its next quarterly update.
Three dates and three signals
On September 28, 2026, Redcare raised full-year 2026 total revenue growth guidance to 16% to 18% from 15% to 17%, while German prescription revenue guidance increased to EUR 730 million to EUR 760 million from EUR 680 million to EUR 720 million, according to Redcare Pharmacy. On October 7, 2026, Berenberg raised its target from EUR 94.00 to EUR 102.00 and MPCM lifted its target from EUR 116.00 to EUR 120.00, as Finanztrends reported. On October 14, 2026, the company installed Schmid von Linstow as CEO following consultation with shareholders, according to EQS News.
What does the guidance mean for margins?
The immediate test is whether prescription growth can translate into profitable scale. The September 28 guidance keeps the adjusted EBITDA margin target at 2.5% to 3.0% for 2026, even as German prescription revenue had grown 56% in the third quarter and the electronic-prescription customer score reached 80 in August, according to Redcare Pharmacy. That combination makes the next report more important than the target revisions alone: revenue acceleration is visible, but the margin range remains the operating constraint.
The next reporting dates
Redcare Pharmacy is scheduled to publish its interim statement for the third quarter of 2026 on October 29, 2026, followed by the annual report for 2026 on March 4, 2027, according to the company's investor-relations calendar.
Stock trades above the Xetra close
The intraday price of EUR 77.63 at Lang & Schwarz on October 21, 2026, at 11:15 a.m. CEST stood EUR 1.68, or 2.21 percent, above the Xetra close of October 20, 2026, at EUR 75.95. The stock remained below its 52-week high of EUR 82.70 while the current market capitalization was EUR 1.6 billion.
The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy facts
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC
- Primary exchange: Frankfurt Stock Exchange, Prime Standard
- Price Lang & Schwarz (as of October 21, 2026, 11:15 a.m. CEST): EUR 77.63
- Change versus Xetra close: plus 2.21 percent
- Xetra close (October 20, 2026): EUR 75.95
- Market capitalization: EUR 1.6 billion (as of October 21, 2026)
- 52-week range: EUR 30.20-EUR 82.70 (as of October 21, 2026)
- Sector / Industry: Healthcare / Medical - Distribution
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report SDAX.
